Brand Name
Aranesp
Generic Name
Darbepoetin
View Brand Information FDA approval date: June 07, 2006
Classification: Erythropoiesis-stimulating Agent
Form: Injection, Solution
What is Aranesp (Darbepoetin)?
Aranesp is an erythropoiesis-stimulating agent indicated for the treatment of anemia due to: Chronic Kidney Disease in patients on dialysis and patients not on dialysis.
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment
Related Latest Advances
There is no latest advances for this treatment